Pharmaceutical Executive Digital Edition - May 2011
Sizing Up For Success
Malaysia: The Overlooked Emerging Market
Rising income per capita and a budding consumer health consciousness are fueling a CAGR of 9.5%, giving investors plenty of room to expand market penetration
The Cloud and Beyond
Cloud computing is slowly but surely becoming the IT platform of choice for the industry. Pharm Exec looks at how it now affects nearly every aspect of the pharma business.
High-Risks to High Reward
According to Eli Lilly, managing alliances requires more than good people skills
UK Stakeholders Have Their Say on Value-Based Pricing
The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance
Expanded Liability for Generic, Brand Manufacturers Ahead?
To what extent are generics companies obligated by law to request labeling changes with FDA?
Using Social Networks to Guide Product Spend
Online sentiment analysis monitoring can help biopharma resource managers make crucial decisions
Blame the Driver, Not the Car
Why is building a successful marketing program so difficult? It should be simple, if your product is worth marketing.
12th Annual Pharm Exec 50
Who's taken this year's top spot? Find out in Pharm Exec's annual run-down of the world's Top 50 pharma companies.
iDeal Tool of Sales Trade
The sleek, portable iPad, coupled with customized apps, gives sales reps a leg up
The Elusive Single-Point-of-Entry
Considering Big Pharma's trade objectives, the success of regional regulatory harmonization is not insignificant
Outrage Over Drug Prices
Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies
Seeing Through the Transparency Directive
The EU is largely powerless when it comes to policies over pricing and reimbursement
On Tour with Merck's Robots
A factory tour to examine Merck's automated robots-and the human minds that inspire them
Keeping Your Place on the Nifty 50
What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era.
Out of Control
The pharmaceutical industry needs to use new and better data to accurately measure how much it is willing to invest in avoiding plan control
